NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. GlucaGen® HypoKit®

    (glucagon [rDNA Origin] for injection)

  4. Levemir®

    (insulin detemir [rDNA origin] injection)

  5. Norditropin®

    (somatropin (rDNA origin) injection)

  6. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  7. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  8. NovoSeven® RT

    Coagulation Factor VIIa (Recombinant) Room
    Temperature Stable

  9. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

Pharmacology

For patients with type 2 diabetes Levemir®: designed with consistency in mind

  • Levemir®â€”the only basal insulin that remains soluble both before and after injection8
  • Unlike insulin glargine and NPH insulin, Levemir® does not form microprecipitates or crystals when injected8

The pharmacology of Levemir® provides a prolonged duration of action8

  • 1Levemir® molecules are absorbed from the injection site at a slow, sustained rate due to strong molecular self-association and binding to a small amount of albumin. The albumin binding of Levemir® can act as a buffer against rapid or irregular changes, for instance, in insulin absorption8
  • 2In the bloodstream, the Levemir® molecules are transported to 3 target tissues, where they interact with the receptors
  • Levemir® provides a prolonged duration of action for a consistent blood glucose response9

  1. Levemir® (insulin detemir [rDNA origin] injection) Indications and Usage

    Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

    Levemir® Important Safety Information

    Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

    Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

    Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir® should not be diluted or mixed with any other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

    Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

    Please see Prescribing Information.

Levemir®, NovoLog®, NovoLog® Mix 70/30, GlucaGen®, HypoKit®, and FlexPen® are registered trademarks of Novo Nordisk A/S. NovoSeven® RT and Norditropin® are registered trademarks of Novo Nordisk Health Care AG. Activella® 1.0 mg/0.5 mg, Activella® 0.5 mg/0.1 mg, and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.